An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX when administered by intramuscular route or subcutaneous route to subjects >=50 years of age.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
Indications Herpes zoster
Focus Pharmacodynamics
Sponsors Merck Sharp & Dohme; sanofi pasteur MSD

01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
10 Apr 2013 Planned End Date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
20 Sep 2012 Planned end date changed from 1 Jun 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com